As of Friday close, Protagonist Therapeutics Inc.’s (NASDAQ:PTGX) stock was up $0.38, moving up 2.03 percent to $19.13. The average number of shares traded per day over the past five days has been 612,980 shares. 3 times new highs have been achieved over the past 5 days, with a $0.22 gain in that time frame. In the last twenty days, the average volume was 636,530, while in the previous 50 days, it was 1,131,734.
Since last month, PTGX stock retreated -3.87%. Shares of the company fell to $17.82 on 08/09/23, the lowest level in the past month. A 52-week high of $30.10 was reached on 06/12/23 after having rallying from a 52-week low of $7.24. Since the beginning of this year, PTGX’s stock price has risen by 75.34% or $8.22, and marked a new high 32 times. However, the stock has declined by -36.45% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
In the three months ended June 29, Protagonist Therapeutics Inc.’s quick ratio stood at 12.00, while its current ratio was 12.00, showing that the company is able to pay off its debt. Based on annual data, PTGX earned $157.95 million in gross profit and brought in $26.58 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -60.90%. Return on equity (ROE) for the past 12 months was -56.80%.
While analysts expected Protagonist Therapeutics Inc. to report -$0.65 quarterly earnings, the actual figure was -$0.68 per share, beating the consensus estimate by -4.60%. During the quarter, the company generated -$42.49 million in EBITDA. The liabilities of Protagonist Therapeutics Inc. were 26.4 million at the end of its most recent quarter ended June 29, and its total debt was $2.45 million. The value of shareholders’ equity is $57.53 million.
Technical Picture
This quick technical analysis looks at Protagonist Therapeutics Inc.’s (PTGX) price momentum. With a historical volatility rate of 31.39%, the RSI 9-day stood at 49.25% on 18 August.
With respect to its five-day moving average, the current Protagonist Therapeutics Inc. price is up by +1.16% percent or $0.22. At present, PTGX shares trade -4.35% below its 20-day simple moving average and -12.09% percent below its 100-day simple moving average. However, the stock is currently trading approximately -34.01% below its SMA50 and +136.17% above its SMA200.
Stochastic coefficient K was 58.83% and Stochastic coefficient D was 54.60%, while ATR was 0.74. Given the Stochastic reading of 79.88% for the 14-day period, the RSI (14) reading has been calculated as 42.18%. As of today, the MACD Oscillator reading stands at 0.10, while the 14-day reading stands at 0.05.
Analyst Ratings
Protagonist Therapeutics Inc. (PTGX) has been rated Buy by analysts. According to 0 brokerage firms, PTGX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Protagonist Therapeutics Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $37.00, the current consensus forecast for the stock is $35.00 – $49.00. Based on these forecasts, analysts predict Protagonist Therapeutics Inc. (PTGX) will achieve an average price target of $39.00.
